company background image
CMPS logo

COMPASS Pathways NasdaqGS:CMPS Stock Report

Last Price

US$4.14

Market Cap

US$387.3m

7D

-1.0%

1Y

-44.2%

Updated

29 May, 2025

Data

Company Financials +

COMPASS Pathways plc

NasdaqGS:CMPS Stock Report

Market Cap: US$387.3m

CMPS Stock Overview

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. More details

CMPS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

COMPASS Pathways plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for COMPASS Pathways
Historical stock prices
Current Share PriceUS$4.14
52 Week HighUS$8.54
52 Week LowUS$2.49
Beta2.28
1 Month Change9.81%
3 Month Change5.34%
1 Year Change-44.20%
3 Year Change-53.22%
5 Year Changen/a
Change since IPO-85.72%

Recent News & Updates

Compass Pathways: Psychedelic Innovator Forging Independent Path With Competition Nearing

May 14

Recent updates

Compass Pathways: Psychedelic Innovator Forging Independent Path With Competition Nearing

May 14

Compass Pathways: Betting On The Future Of Psilocybin Therapy

Feb 28

Does COMPASS Pathways (NASDAQ:CMPS) Have A Healthy Balance Sheet?

Jan 04
Does COMPASS Pathways (NASDAQ:CMPS) Have A Healthy Balance Sheet?

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Nov 01

Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision

Aug 19

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Jul 08

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

May 23

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Feb 08

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Dec 06
Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Booker again pushes for easier access to psychedelics for terminally ill patients

Oct 19

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

COMPASS Pathways And The Trillion Dollar Opportunity

Aug 11

COMPASS Pathways ADS Q2 2022 Earnings Preview

Aug 03

COMPASS Pathways names new CEO

Jul 19

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

Jun 30

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Apr 28
We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Checking In On Compass Pathways

Mar 02

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Dec 29
We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Compass Pathways: Psychedelics For Mental Health

Nov 23

Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy

Sep 17

Shareholder Returns

CMPSUS BiotechsUS Market
7D-1.0%2.6%1.2%
1Y-44.2%-9.1%12.5%

Return vs Industry: CMPS underperformed the US Biotechs industry which returned -9.6% over the past year.

Return vs Market: CMPS underperformed the US Market which returned 11.5% over the past year.

Price Volatility

Is CMPS's price volatile compared to industry and market?
CMPS volatility
CMPS Average Weekly Movement10.7%
Biotechs Industry Average Movement12.2%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.1%

Stable Share Price: CMPS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CMPS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2020166Kabir Nathcompasspathways.com

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

COMPASS Pathways plc Fundamentals Summary

How do COMPASS Pathways's earnings and revenue compare to its market cap?
CMPS fundamental statistics
Market capUS$387.35m
Earnings (TTM)-US$137.80m
Revenue (TTM)n/a
0.0x
P/S Ratio
-2.8x
P/E Ratio

Is CMPS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMPS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$137.80m
Earnings-US$137.80m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio15.6%

How did CMPS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 03:50
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COMPASS Pathways plc is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.